slotkoers
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
1,57 USD | -.--% | -0,63% | -54,89% |
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 3,22 mln. 3,5 mln. 3,29 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | - | Nettowinst (verlies) 2025 * | - | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-
| K/w-verhouding 2025 * |
-
| Werknemers | 10 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 99,11% |
Recentste transcriptie over Altamira Therapeutics Ltd.
1 week | -0,63% | ||
1 maand | -24,15% | ||
3 maanden | -15,14% | ||
6 maanden | -46,23% | ||
Lopend jaar | -54,89% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Thomas Meyer
CEO | Chief Executive Officer | 56 | 01-04-03 |
Marcel Gremaud
DFI | Director of Finance/CFO | 66 | 01-11-21 |
Covadonga Pañeda
COO | Chief Operating Officer | 51 | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Alain Munoz
BRD | Director/Board Member | 75 | 01-03-18 |
Mats Blom
BRD | Director/Board Member | 59 | 01-04-17 |
Thomas Meyer
CEO | Chief Executive Officer | 56 | 01-04-03 |
Datum | Koers | Variatie | Volume |
---|---|---|---|
30-04-24 | 1,57 | -.--% | 44 304 |
29-04-24 | 1,57 | -7,10% | 49 747 |
26-04-24 | 1,69 | +5,62% | 166 284 |
25-04-24 | 1,6 | +11,11% | 322 810 |
24-04-24 | 1,44 | -8,86% | 3 000 617 |
slotkoers Nasdaq, 30 april 2024
Meer koersenKwartaalomzet - Afwijkingspercentage
Vaira. 1 jan. | Kapi. | |
---|---|---|
-54,89% | 3,52 mln. | |
-3,46% | 102 mld. | |
+1,41% | 96,29 mld. | |
+2,13% | 22,18 mld. | |
-15,84% | 21,2 mld. | |
-9,21% | 18,31 mld. | |
-39,98% | 17,38 mld. | |
-14,65% | 16,36 mld. | |
+4,39% | 13,97 mld. | |
+31,35% | 12,17 mld. |